Agenus Inc
AGEN
Market Cap$220.49M
Close$
$-6.07
155.9% downside
Current Fair Value
155.9% downsideOvervalued by 155.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $220.49 Million |
|---|---|
| Enterprise Value | $181.21 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-12.65 |
| Beta | 0.0 |
| Outstanding Shares | 20,999,261 |
| Avg 30 Day Volume | 1,107,256 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.92 |
|---|---|
| PEG | 9.87 |
| Price to Sales | 1.55 |
| Price to Book Ratio | -1.09 |
| Enterprise Value to Revenue | 1.12 |
| Enterprise Value to EBIT | -1.31 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -0.07 |
Revenue Sources
No data
ESG Score
No data
About Agenus Inc
CEO: Garo Armen Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators , pa...